Moshe Sade-Feldman

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

The paper constructs a single-cell splicing atlas of human CD8 T cells and identifies isoform-specific immune checkpoints that enhance effector function and tumor control.

This study develops a zebrafish model of mucosal melanoma by activating an oncogene and inactivating tumor suppressors, revealing that internal melanocytes give rise to tumors with distinct transcriptional and chromatin features.

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

The paper identifies CREB5 as a driver of immunotherapy resistance in melanoma by promoting collagen matrix deposition, which activates LAIR1 signaling on immune cells.

This study investigates the combination of TLR8 agonism and PD-1 blockade in HNSCC patients, finding increased innate immune activation and dendritic cell-T cell interactions.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

This paper introduces MAS-ISO-seq, a method to boost throughput of long-read RNA sequencing for isoform discovery, showing improved detection of differentially spliced genes and cell clustering in T cells.

The paper develops DNA- and RNA-based models combining immune and tumor features to predict outcomes of checkpoint inhibition in melanoma.

The paper uses plasma proteomics to identify tissue-specific cell death and cell-cell interaction mediators in severe COVID-19 patients, linking them to survival outcomes and viral infection effects.